论文部分内容阅读
目的探讨和观察腹腔热灌注化疗在卵巢恶性肿瘤术后的应用及临床疗效。方法将符合条件的60例患者随机分为两组。治疗组35例,为顺铂腹腔热灌注联合紫杉醇静脉双径路化疗;对照组25例,为单行TP方案静脉化疗。观察两组CA125下降,腹水控制率及不良反应。结果两组术后的CA125水平无明显差异(P>0.05)。热灌注后治疗组平均CA125值降至23.5 U/ml,对照组平均CA125值降至56.7 U/ml,差异有统计学意义(P<0.05)。两组的腹水控制率(CR+PR)分别为80%和52%,差异具有统计学意义(P<0.05)。两组的不良反应差异有统计学意义(P<0.05)。结论采用顺铂腹腔热灌注联合静脉化疗治疗卵巢癌的疗效优于单纯静脉化疗,且不良反应小,值得临床推广应用。
Objective To investigate and observe the application of intraperitoneal hyperthermic chemotherapy in postoperative ovarian cancer and its clinical efficacy. Methods 60 eligible patients were randomly divided into two groups. The treatment group of 35 cases of cisplatin intraperitoneal hot perfusion combined with paclitaxel intravenous dual-path chemotherapy; control group of 25 cases, a single TP regimen chemotherapy. Two groups were observed CA125 decreased ascites control rate and adverse reactions. Results There was no significant difference in CA125 levels between the two groups (P> 0.05). The average CA125 of the treatment group after heat-perfusion decreased to 23.5 U / ml, while the control group’s average CA125 value dropped to 56.7 U / ml, the difference was statistically significant (P <0.05). The ascites control rates (CR + PR) in both groups were 80% and 52%, respectively, with statistical significance (P <0.05). Adverse reactions between the two groups were statistically significant (P <0.05). Conclusion Intraperitoneal hot perfusion with cisplatin combined with intravenous chemotherapy for ovarian cancer is superior to simple intravenous chemotherapy, and the adverse reactions are small, worthy of clinical application.